Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.12−1.38 (-7.89%)
Close on Nov 13, 2026Market cap $117.10MP/E –Yield –
Cue Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Cue Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $77.19M, up 133.8% year over year. For fiscal 2025 it was $37.74M, up 4.0% from the year before. The highest annual figure on record is $41.35M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.74M | +4.0% |
| FY2024 | Dec 31, 2024 | $36.30M | -11.0% |
| FY2023 | Dec 31, 2023 | $40.80M | +5.8% |
| FY2022 | Dec 31, 2022 | $38.58M | -6.7% |
| FY2021 | Dec 31, 2021 | $41.35M | +23.3% |
| FY2020 | Dec 31, 2020 | $33.55M | +22.0% |
| FY2019 | Dec 31, 2019 | $27.49M | -3.7% |
| FY2018 | Dec 31, 2018 | $28.54M | +51.0% |
| FY2017 | Dec 31, 2017 | $18.90M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $49.01M | +519.6% |
| Q1 FY2026 | Mar 31, 2026 | $6.90M | -19.3% |
| Q4 FY2025 | Dec 31, 2025 | $16.53M | +130.1% |
| Q3 FY2025 | Sep 30, 2025 | $4.75M | -49.3% |
| Q2 FY2025 | Jun 30, 2025 | $7.91M | -17.0% |
| Q1 FY2025 | Mar 31, 2025 | $8.55M | -16.2% |
| Q4 FY2024 | Dec 31, 2024 | $7.18M | -34.0% |
| Q3 FY2024 | Sep 30, 2024 | $9.38M | -5.0% |
| Q2 FY2024 | Jun 30, 2024 | $9.53M | -10.5% |
| Q1 FY2024 | Mar 31, 2024 | $10.20M | +8.6% |
| Q4 FY2023 | Dec 31, 2023 | $10.89M | -3.9% |
| Q3 FY2023 | Sep 30, 2023 | $9.87M | +30.4% |
| Q2 FY2023 | Jun 30, 2023 | $10.65M | +11.0% |
| Q1 FY2023 | Mar 31, 2023 | $9.39M | -6.9% |
| Q4 FY2022 | Dec 31, 2022 | $11.33M | -1.5% |
| Q3 FY2022 | Sep 30, 2022 | $7.57M | -32.9% |
| Q2 FY2022 | Jun 30, 2022 | $9.59M | +9.5% |
| Q1 FY2022 | Mar 31, 2022 | $10.08M | +2.7% |
| Q4 FY2021 | Dec 31, 2021 | $11.50M | +43.7% |
| Q3 FY2021 | Sep 30, 2021 | $11.29M | +50.2% |
| Q2 FY2021 | Jun 30, 2021 | $8.76M | +7.9% |
| Q1 FY2021 | Mar 31, 2021 | $9.82M | -0.9% |
| Q4 FY2020 | Dec 31, 2020 | $8.00M | +14.9% |
| Q3 FY2020 | Sep 30, 2020 | $7.52M | +41.8% |
| Q2 FY2020 | Jun 30, 2020 | $8.12M | +18.2% |
| Q1 FY2020 | Mar 31, 2020 | $9.91M | +18.6% |
| Q4 FY2019 | Dec 31, 2019 | $6.96M | +2.1% |
| Q3 FY2019 | Sep 30, 2019 | $5.30M | -48.6% |
| Q2 FY2019 | Jun 30, 2019 | $6.87M | +26.8% |
| Q1 FY2019 | Mar 31, 2019 | $8.35M | +43.5% |
| Q4 FY2018 | Dec 31, 2018 | $6.82M | -24.4% |
| Q3 FY2018 | Sep 30, 2018 | $10.31M | +157.7% |
| Q2 FY2018 | Jun 30, 2018 | $5.41M | +58.4% |
| Q1 FY2018 | Mar 31, 2018 | $5.82M | +136.4% |
| Q4 FY2017 | Dec 31, 2017 | $9.02M | – |
| Q3 FY2017 | Sep 30, 2017 | $4.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.42M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.46M | – |
See a number that looks wrong?